Isatuximab-irfc with bortezomib, lenalidomide, and dexamethasone is approved by the USFDA for newly diagnosed multiple myeloma
Isatuximab-irfc with bortezomib, lenalidomide, and dexamethasone is approved by the USFDA for newly diagnosed multiple myeloma